logo
Plus   Neg
Share
Email

Burberry Announces Three-month Pay Cut For Senior Leaders, Directors

Retailer Burberry Group plc (BRBY.L), in its Covid-19 update on Friday, said its senior leaders will take a voluntary 20 percent pay cut from April through June.

Further, the Board of Directors has agreed to a voluntary 20 percent reduction in their base salary and fees from April through June, with the equivalent cash amount to be donated to the Burberry Foundation COVID-19 Community Fund.

Over the next few months, the company will continue to maintain base pay for all employees who are unable to fulfil their roles because of store or site closures. The company also said it will not rely on government support for jobs in the UK where more than a third of its employees are based.

The company's trench coat factory in Castleford is now manufacturing non-surgical gowns and supplying them to the UK National Health Service.

The firm is also sourcing surgical masks through supply chain and supplying them to the NHS and charities. To date, the company has donated more than 100,000 pieces of PPE.

The company will now publish annual preliminary results on May 22 rather than May 14.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT